Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma

References

• Armitage J O, Weisenburger D D. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780–2795
   PubMed Web of Science ®Google Scholar
• Gallagher C, Gregory W, Jones A, Stansfeld A, Richards M, Dhaliwal H, et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Horning S. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 1993; 20: 75–88
   PubMed Web of Science ®Google Scholar
• Rohatiner A, Lister T. The clinical course of follicular lymphoma. Best Pract Res Clin Haematol 2005; 18: 1–10
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, White J, Armitage J, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258–1265
   PubMed Web of Science ®Google Scholar
• Swenson W, Wooldridge J, Lynch C, Forman-Hoffman V, Chrischilles E, Link B. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005; 23: 5019–5026
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, Williams M, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423
   PubMed Web of Science ®Google Scholar
• Services CfMaM. ASP Drug Pricing Files. Center for Medicare and Medicaid Services. 2006
   Google Scholar
• Genentech I. U.S. BL 103705/5247 Amendment: Rituximab. Federal Drug Administration. 2007
   Google Scholar
• Network NCC. NCCN(R) Practice Guidelines in Oncology, v.1.2007: non-Hodgkin's lymphomas. National Comprehensive Cancer Network. 2007
   Google Scholar
• Forstpointner R, Unterhalt M, Dreyling M, Bock H P, Repp R, Wandt H, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008
   PubMed Web of Science ®Google Scholar
• Hochster H S, Weller W E, Ryan T, Habermann T M, Gascoyne R, Frankel S R, Horning S J. Results of E1496: a Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma. ASCO Annual Meeting. New Orleans. J Clin Oncol 2004; 22: 6502
   Google Scholar
• van Oers M H, Klasa R, Marcus R E, Wolf M, Kimby E, Gascoyne R D, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301
   PubMed Web of Science ®Google Scholar
• Waters T, Bennett C, Pajeau T, Sobocinski K, Klein J, Rowlings P, et al. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?. Bone Marrow Transplant 1998; 21: 641–650
   PubMed Web of Science ®Google Scholar
• Hoover D, Crystal S, Kumar R, Sambamoorthi U, Cantor J. Medical expenditures during the last year of life: findings from the 1992 – 1996 Medicare current beneficiary survey. Health Serv Res 2002; 37: 1625–1642
   PubMed Web of Science ®Google Scholar
• Wild D, Walker M, Pettengell R, Lewis G, Briggs A, editors. Utility elicitation in patients with follicular lymphoma. 11th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2006; Philadelphia, PA. Value Health; 2006. A411 (Abstract PCN62) p.
   Google Scholar
• Guadagnolo B, Punglia R, Kuntz K, Mauch P, Nq A. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006; 24: 4116–4122
   PubMed Web of Science ®Google Scholar
• Lipscomb J, Weinstein M, Torrance G. Time preference. Cost-Effectiveness in Health and Medicine, M Gold, J Siegel, L Russell, M Weinstein. Oxford University Press, New York 1996; 214–246
   Google Scholar
• Statistics BoL. BLS. Consumer Price Index for all Urban Consumers (CPI-U): U.S. City Average, by expenditure category and commodity and service group (Table 1). Bureau of Labor Statistics. 2006
   Google Scholar
• Atkins D, Best D, Briss P, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
   PubMed Web of Science ®Google Scholar
• Braithwaite R, Roberts M, Justice A. Incorporating quality of evidence into decision analytic modeling. Ann Intern Med 2007; 146: 133–141
   PubMed Web of Science ®Google Scholar
• Archuleta T, Armitage J. Advances in follicular lymphoma. Semin Oncol 2004; 31: 66–71
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732
   PubMed Web of Science ®Google Scholar
• Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). ASCO Meeting Abstracts. J Clin Oncol 2006; 24: 7508
   Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali K H, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986–1992
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius J F, Trelle S, Skoetz N, Reiser M, Kober T, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706–714
   PubMed Web of Science ®Google Scholar
• Best J H, Hornberger J, Proctor S J, Omnes L F, Jost F. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005; 8: 462–470
   PubMed Web of Science ®Google Scholar
• Groot M T, Lugtenburg P J, Hornberger J, Huijgens P C, Uyl-de Groot C A. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005; 74: 194–202
   PubMed Web of Science ®Google Scholar
• Hornberger J C, Best J H. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005; 103: 1644–1651
   PubMed Web of Science ®Google Scholar
• Maturi B, Mikhael JR, Dunlop WCN, Tilden DT, Wong L, editors. Maintenance Therapy with Rituximab for Follicular Lymphoma Is Cost-Effective—A Canadian Perspective. Blood (Suppl.) 2006;16:343.
   Google Scholar
• Neumann P, Sandberg P, Bell C, Stone P, Chapman R. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) 2006; 19: 92–109
   Web of Science ®Google Scholar